Business
Rafarma Pharmaceuticals strengthens its position in Central Asia
Rafarma Pharmaceuticals strengthens its position in Central Asia.
About this update from Rafarma Pharmaceuticals, Inc. (wy)
[{"type":"text","content":"\n Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the territory of the innovative research and production pharmaceutical cluster \"Tashkent Pharma Park\". Rafarma Pharmaceuticals is not new to the Central Asian market, the company has been operating there for a long time and plans to increase its presence by creating local production. Over the next three years, the company plans to build a plant there designed according to all Industry 4.0 standards: a flexible industrial base that can easily, quickly and cost-effectively undergo significant modernization and modification depending on production tasks, drugs and required technologies. The plant will include two production units: production of sterile preparations for the market of Uzbekistan and the countries of Central Asiaproduction of fractionated blood plasma elements and other products in the form of frozen plasma and blood factors, as well as the development of a network of laboratories for plasma procurement Rafarma Pharmaceuticals is the initiator of the development of new approaches to the drugs from blood plasma creation in Uzbekistan. The company's project, which became a part of a list of measures to accelerate the development of the pharmaceutical industry in Uzbekistan in 2022-2026, will consist of two stages: the creation of a modern certified laboratories network for plasma collection and then the creation of a plant for its fractionation. In 4-5 years, the business's expected revenue will be tens of millions of dollars. To date, the country's government is working on legislative changes in the principles of working with blood plasma in the medical sector and is also preparing documents to allow the based on it medicine export. The implementation of the Rafarma Pharmaceuticals project will begin as soon as the necessary regulatory framework creates in the government, which is expected to happen soon. Uzbekistan ranks first among the Eastern Europe countries in terms of economic growth, and the expected changes will only strengthen the country's influence in the pharmaceutical market. ABOUT RAFARMA PHARMACEUTICALS: Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutio...